查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1871160

基因组学市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

Genomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球基因组学市场价值为 390 亿美元，预计到 2034 年将以 15.4% 的复合年增长率增长至 1,620 亿美元。

基因组学市场 - IMG1

基因组学产业正快速扩张，其发展动力源自于慢性病和遗传性疾病日益普遍以及精准医疗的兴起。基因组学透过分析生物体的全部DNA组成（包括所有基因），为疾病机制、基因变异和个人化治疗方案的发展提供了变革性的见解。 DNA定序、基因编辑和生物资讯学等技术的进步，以及人工智慧和巨量资料分析的日益普及，进一步推动了基因组学市场的发展。基因组学在医疗保健和生命科学领域的应用，加速了其在诊断、药物研发、生殖健康、法医学和农业等领域的普及。如今，基因组学在肿瘤学、罕见疾病诊断、药物基因组学和伴随诊断等领域至关重要，医疗保健系统正日益整合基因组学工具，以实现标靶治疗、减少药物不良反应并简化药物研发流程。持续的监管支持，以及生技公司和研究机构之间的合作，正巩固基因组学作为预测性和个人化医疗保健基石的地位。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 390亿美元
预测值 1620亿美元
复合年增长率 15.4%

2024年，产品板块占据67.1%的市场份额，预计到2034年将达到1,057亿美元，年复合成长率达15.1%。此类别涵盖科学研究和临床应用中使用的关键仪器和耗材。聚合酶炼式反应系统、微阵列和新一代定序平台等技术对于高效、准确、高通量地产生大尺度基因组资料至关重要。试剂、定序试剂盒和样品製备材料等耗材具有重要价值，因为它们是实验室流程中持续必需的。仪器和耗材技术的不断升级正在推动其在医院、学术研究和生物製药行业的广泛应用。

2024年，定序领域创造了148亿美元的收入。这项技术仍然是关键的成长引擎，这得益于其在精确性、可扩展性和成本效益方面的进步。高通量定序方法能够同时读取大量的DNA和RNA序列，为基因组和转录组研究提供前所未有的细节。这些创新加速了科学发现，改善了疾病诊断，并扩展了定序在临床应用中的作用，尤其是在精准医疗和基因筛检领域。定序平台的持续进步正在确保其可近性，并使其更好地融入医疗保健和研究工作流程。

预计到2024年，北美基因组学市场份额将达到42.6%，这反映了其强大的研究生态系统、大量的政府和私人投资，以及基因组学在医疗保健领域的广泛应用。该地区对精准医疗计划的重视、活跃的临床试验活动以及生物技术机构与学术机构之间的合作，都为持续创新提供了支持。对个人化疗法、先进诊断和疾病早期检测技术的需求依然十分旺盛。随着各大公司在定序、生物资讯学和诊断技术方面取得领先进展，北美正透过创新和普及性，持续塑造全球基因组学格局。

全球基因体学市场的主要参与者包括赛默飞世尔科技（Thermo Fisher Scientific）、凯杰（QIAGEN）、安捷伦科技（Agilent Technologies）、牛津奈米孔科技公司（Oxford Nanopore Technologies）、Bio-Rad Laboratories、丹纳赫（Danaher）、罗氏（F. Hoffy） Genetics）、华大基因（BGI Genomics）、艾本多夫（Eppendorf）、科乐基因（Color Genomics）、太平洋生物科学公司（Pacific Biosciences of California）、英伟达（NVIDIA）、奎斯特诊断（Quest Diagnostics）和艾鲁米纳（Illumina）。为了巩固自身地位，基因组学产业的主要参与者正积极推行以技术创新、合作和扩张为核心的策略。各公司正大力投资先进的定序平台和基于云端的生物资讯工具，以提高资料的精确性和可近性。与製药公司和研究机构的策略合作正在推动基因组学在药物研发和临床试验中的应用。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

  • 产业生态系分析
    • 供应商格局
    • 每个阶段的价值增加
    • 影响价值链的因素
  • 产业影响因素
    • 成长驱动因素
      • 遗传性和慢性疾病的盛行率不断上升
      • DNA定序与基因编辑技术的进步
      • 精准医疗的日益普及
      • 政府对基因组学研究的倡议和资助
    • 产业陷阱与挑战
      • 基因资料相关的伦理和隐私问题
      • 高成本和可负担性问题
    • 市场机会
      • 开发经济高效且快速的定序技术
      • 人工智慧与机器学习的融合以增强基因组资料分析
  • 成长潜力分析
  • 监管环境
    • 北美洲
      • 我们
      • 加拿大
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 技术格局
    • 当前技术趋势
    • 新兴技术
  • 未来市场趋势
  • 管道分析
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估算与预测：依类型划分，2021-2034年

  • 主要趋势
  • 产品
    • 仪器
    • 耗材和试剂
  • 服务
    • 基于NGS的服务
    • 核心基因组学服务
    • 生物标誌物翻译服务
    • 计算服务
    • 其他服务

第六章：市场估计与预测：依技术划分，2021-2034年

  • 主要趋势
  • PCR（聚合酶炼式反应）
  • 定序
  • 微阵列
  • 核酸萃取与纯化
  • 其他技术

第七章：市场估计与预测：依应用领域划分，2021-2034年

  • 主要趋势
  • 诊断
  • 药物发现与开发
  • 精准医疗
  • 农业和动物研究
  • 其他应用

第八章：市场估算与预测：依最终用途划分，2021-2034年

  • 主要趋势
  • 医院和诊所
  • 研究中心、学术机构和政府机构
  • 製药和生物技术公司
  • 其他最终用途

第九章：市场估计与预测：依地区划分，2021-2034年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：公司简介

  • Agilent Technologies
  • BGI Genomics
  • Bio-Rad Laboratories
  • Color Genomics
  • Danaher
  • Eppendorf
  • Eurofins Scientific
  • F. Hoffmann-La Roche
  • Illumina
  • Myriad Genetics
  • NVIDIA
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California
  • QIAGEN
  • Quest Diagnostics
  • Thermo Fisher Scientific
简介目录
Product Code: 14946

The Global Genomics Market was valued at USD 39 Billion in 2024 and is estimated to grow at a CAGR of 15.4% to reach USD 162 Billion by 2034.

Genomics Market - IMG1

The genomics industry is expanding swiftly, driven by the increasing prevalence of chronic and genetic disorders and the heightened emphasis on precision medicine. Genomics, which examines an organism's full DNA makeup, including all genes, offers transformative insights into disease mechanisms, genetic variations, and individualized treatment pathways. The market's momentum is further supported by technological progress in DNA sequencing, gene editing, and bioinformatics, along with the growing application of artificial intelligence and big data analytics. The use of genomics across healthcare and life sciences has accelerated its adoption in diagnostics, drug discovery, reproductive health, forensics, and agriculture. With genomics now vital to areas such as oncology, rare disease diagnosis, pharmacogenomics, and companion diagnostics, healthcare systems are increasingly integrating genomic tools to enable targeted therapies, reduce adverse drug reactions, and streamline drug development. Continuous regulatory support, combined with collaborative efforts between biotechnology firms and research institutions, is reinforcing genomics as the foundation of predictive and personalized healthcare.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$39 Billion
Forecast Value$162 Billion
CAGR15.4%

The products segment held 67.1% share in 2024 and is expected to reach USD 105.7 Billion by 2034, growing at a CAGR of 15.1%. This category includes essential instruments and consumables used in research and clinical applications. Technologies such as polymerase chain reaction systems, microarrays, and next-generation sequencing platforms are central to generating large-scale genomic data with improved efficiency, accuracy, and throughput. Consumables, including reagents, sequencing kits, and sample preparation materials, hold significant value as they are continuously required for laboratory processes. The ongoing technological upgrades in both instruments and consumables are helping expand their adoption in hospitals, academic research, and biopharmaceutical industries.

The sequencing segment generated USD 14.8 Billion in 2024. This technology remains a key growth engine, supported by advancements in precision, scalability, and cost-effectiveness. High-throughput sequencing methods enable simultaneous reading of extensive DNA and RNA sequences, offering unparalleled detail for genome and transcriptome studies. These innovations have accelerated scientific discovery, improved disease diagnosis, and expanded the role of sequencing in clinical applications, particularly in precision medicine and genetic screening. Continuous progress in sequencing platforms is ensuring their accessibility and integration into healthcare and research workflows.

North America Genomics Market held a 42.6% share in 2024, reflecting its strong research ecosystem, significant government and private investment, and widespread adoption of genomics in healthcare. The region's focus on precision medicine initiatives, robust clinical trial activity, and collaborations between biotechnology and academic institutions support continuous innovation. The demand for personalized therapies, advanced diagnostics, and early disease detection technologies remains particularly high. With major companies leading advancements in sequencing, bioinformatics, and diagnostic technologies, North America continues to shape the global genomics landscape through innovation and accessibility.

Leading companies operating in the Global Genomics Market include Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Oxford Nanopore Technologies, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Eurofins Scientific, Myriad Genetics, BGI Genomics, Eppendorf, Color Genomics, Pacific Biosciences of California, NVIDIA, Quest Diagnostics, and Illumina. To strengthen their position, major players in the genomics industry are pursuing strategies centered on technology innovation, partnerships, and expansion. Companies are investing heavily in advanced sequencing platforms and cloud-based bioinformatics tools to enhance data precision and accessibility. Strategic collaborations with pharmaceutical firms and research institutions are enabling the integration of genomics in drug discovery and clinical trials.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Type trends
    • 2.2.3 Technology trends
    • 2.2.4 Application trends
    • 2.2.5 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factors affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of genetic and chronic diseases
      • 3.2.1.2 Advancements in DNA sequencing and gene editing technologies
      • 3.2.1.3 Increasing adoption of precision medicine
      • 3.2.1.4 Government initiatives and funding for genomics research
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Ethical and privacy concerns around genetic data
      • 3.2.2.2 High cost and affordability issues
    • 3.2.3 Market opportunities
      • 3.2.3.1 Development of affordable and rapid sequencing technologies
      • 3.2.3.2 Integration of AI and machine learning for enhanced genomic data analysis
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
      • 3.4.1.1 U.S.
      • 3.4.1.2 Canada
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Future market trends
  • 3.7 Pipeline analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Products
    • 5.2.1 Instruments
    • 5.2.2 Consumables and reagents
  • 5.3 Services
    • 5.3.1 NGS-based services
    • 5.3.2 Core genomics services
    • 5.3.3 Biomarker translation services
    • 5.3.4 Computational services
    • 5.3.5 Other services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 PCR (polymerase chain reaction)
  • 6.3 Sequencing
  • 6.4 Microarray
  • 6.5 Nucleic acid extraction and purification
  • 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Diagnostics
  • 7.3 Drug discovery and development
  • 7.4 Precision medicine
  • 7.5 Agriculture and animal research
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Research centers and academic and government institutes
  • 8.4 Pharmaceutical and biotechnology companies
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Agilent Technologies
  • 10.2 BGI Genomics
  • 10.3 Bio-Rad Laboratories
  • 10.4 Color Genomics
  • 10.5 Danaher
  • 10.6 Eppendorf
  • 10.7 Eurofins Scientific
  • 10.8 F. Hoffmann-La Roche
  • 10.9 Illumina
  • 10.10 Myriad Genetics
  • 10.11 NVIDIA
  • 10.12 Oxford Nanopore Technologies
  • 10.13 Pacific Biosciences of California
  • 10.14 QIAGEN
  • 10.15 Quest Diagnostics
  • 10.16 Thermo Fisher Scientific